Shaperon Inc.
Financials
Valuation Metrics
Shaperon Inc.'s Market Cap is ₩227B. At end of 2025 it was ₩805B. Ranked #2239 of 2,436 in KR market (top 92%), #1468 of 1,649 on KOSDAQ (top 89%), #225 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 96%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 22.71B KRW | KR#2,239/2,436 Sec#225/234 |
| Revenue | 281.4M KRW | KR#2,398/2,436 Sec#225/234 |
| Net Income | -15.54B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 24.70B KRW | KR#2,351/2,436 Sec#226/234 |
| Net Assets | 21.20B KRW | KR#2,264/2,436 Sec#214/234 |
| Employees | 54 | KR#2,000/2,436 Sec#181/234 |
| Value | ||
| P/B | 1.07x | KR#1,541/2,436 Sec#102/234 |
| P/S | 80.69x | KR#2,379/2,436 Sec#204/234 |
| FCF Yield | -64.00% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -73.31% | KR#2,317/2,436 Sec#212/234 |
| ROA | -62.94% | KR#2,367/2,436 Sec#222/234 |
| Op. Margin | -5640.75% | KR#2,399/2,436 Sec#225/234 |
| Revenue Growth | 454.10% | KR#24/2,436 Sec#6/234 |
| Financial Health | ||
| Debt Ratio | 116.48% | KR#576/2,436 Sec#73/234 |
| Total Debt | 60.8M KRW | KR#2,038/2,436 Sec#195/234 |
| FCF | -14.53B KRW | KR#1,818/2,436 Sec#167/234 |
| Cash | 1.07B KRW | KR#2,333/2,436 Sec#224/234 |
| Current Ratio | 9.30x | KR#114/2,436 Sec#30/234 |
| Performance | ||
| 1Y Return | -78.32% | KR#2,397/2,436 Sec#234/234 |
| 1M Return | -18.71% | KR#2,152/2,436 Sec#214/234 |
| From 52W High | -85.52% | KR#2,409/2,436 Sec#231/234 |
| 1Y MDD | -86.16% | KR#2,387/2,436 Sec#230/234 |
| Trading | ||
| Volume | 1,124,901 shares | KR#124/2,436 Sec#8/234 |
| Foreign Own. | 6.97% | KR#606/2,436 Sec#56/234 |
| Per Share | ||
| EPS | -405 KRW | KR—/2,436 Sec—/234 |
| BPS | 458 KRW | KR#2,396/2,436 Sec#229/234 |
Company Info
SHAPERON, established in 2008 and listed on KOSDAQ in 2022, is a bio-venture company specializing in new drug candidate development. It expanded its global presence by establishing a U.S. subsidiary in 2023. The company possesses the world's first GPCR19 target-based inflammation inhibitor platform and a nanobody antibody development platform, with various therapeutics in clinical development. SHAPERON is accelerating new drug candidate discovery through an AI-based platform, established after its innovative new drug research center in 2023, and is headquartered in Gangnam-gu, Seoul.